Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial

Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-03T19:22:33.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T19:17:09.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-06T19:30:17.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page, replacing the expected study record content. This indicates access is blocked to the NCT03546582 study details.
    Difference
    19%
    Check dated 2026-09-22T22:24:03.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Revision updated from v3.6.6 to v3.7.0, indicating a behind-the-scenes software update. This does not alter the study details or visible content on the page.
    Difference
    0.0%
    Check dated 2026-09-15T21:40:15.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page version was updated from v3.6.5 to v3.6.6, indicating a backend or UI maintenance release. This upgrade does not alter the study content or reported data and is intended for system improvements.
    Difference
    0.0%
    Check dated 2026-09-01T17:48:08.000Z thumbnail image

Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.